4th Jul 2018 09:54
LONDON (Alliance News) - Non-invasive prenatal testing firm Premaitha Health PLC said Wednesday it has appointed Lyn Rees as its new boss and Keng Hsu as chief operating officer, as current Chief Executive Officer Stephen Little becomes executive vice chair.
Rees has served as CEO at BBI Group for nine years, having been at the firm for 18 years.
"During his tenure as Chief Executive Officer, Lyn oversaw the substantial growth of BBI through the execution and integration of a number of acquisitions and by driving an organic growth plan based around product diversification and commercial globalisation," Premaitha said in a statement.
Current CEO Little will become executive vice chairman allowing him to focus on the "continued technological development" at the firm.
Hsu was the former chief financial officer of Premaitha-owned Yourgene Bioscience prior to its acquisition in March 2017. Since then he has played a "key" role in the firm's Asian expansion.
"We are delighted to welcome Lyn to Premaitha, during what is a very exciting phase in our development," Premaitha Chairman Adam Reynolds said. "Lyn's strong track record of driving growth in international markets and securing blue chip partners will be invaluable as we continue to commercialise our technologies."
I would also like to express my sincere thanks to Steve for his outstanding contribution in building Premaitha to where we are today," Reynolds added, "with market leading non-invasive prenatal testing solutions in a growing global market."
"I look forward to working with Steve, Lyn and Keng as we continue to build Premaitha by leveraging our technological capabilities in molecular diagnostics, optimising our routes to market and maximising the Group's international footprint", Reynolds said.
Non-Executive Director Alan Chang will also step down with immediate effect in order to focus on other business interests.
Shares in Premaitha were 0.2% higher at 7.56 pence on Wednesday.